Skip to main content

EVENTS

Miami Medicos

Company Spotlight Event

Company in the Spotlight: Veru, Inc.
Date: May 10, 2022

“Mitch Steiner’s Veru Inc. is impacting the world with its compelling data in reducing death in moderate to severe, hospitalized COVID patients treated with its lead compound, sabazabulin, and its located right here in Miami”

Watch the presentation of how the Veru team imagined and then executed on their novel approach to COVID 19 mortality.

On May 10, 2022, Miami Medicos, in co-sponsorship with HomeOffs, hosted its first ever “Company Spotlight” event highlighting Veru Inc. and its transformational CEO, Dr. Mitch Steiner, in Miami. The event gave us the opportunity to hear the story of Veru’s lead drug candidate, sabizabulin, that showed a 55% reduction in deaths compared with placebo in moderate to severe patients hospitalized for COVID-19.

“If this new drug had been available at the beginning of the COVID pandemic, of the 1,000,000 Americans who’ve died, 550,000 would be home with their families this evening”

Mitch Steiner

Mitchell Steiner, MD, FACS
Vice Chairman and CFO, Miami Medicos

Mitchell Steiner, MD, FACS has served as President and Chief Executive Officer of Veru and as a director of the Company since October 2016. Dr. Steiner was the co-founder of Aspen Park.

MITCHELL S. STEINER, M.D., F.A.C.S.

Has served as President and Chief Executive Officer of Veru and as a director of the Company since October 2016. Dr. Steiner was the co-founder of Aspen Park and served as Aspen Park’s Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NYSE:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men’s health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.